Affimer

Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

Retrieved on: 
화요일, 11월 14, 2023
Webcast, Record, Safety, Annual general meeting, Cytokine release syndrome, Research, Type, Silicon Valley Bank, ASH, Non-Hodgkin lymphoma, CRS, International, Bank statement, Book, Silicon, Insurance, Patient, Genentech, FDA, Hodgkin lymphoma, Lung cancer, International Financial Reporting Standards, GVHD, Monroe Dunaway Anderson, International Accounting Standards Board, IASB, Cholangiocarcinoma, ORR, Roivant Sciences, Cancer, Trial of the century, Financial toxicity, Haematopoietic system, HL, EST, AML, Society, NHL, PTCL, NK, NSCLC, Cryptocurrency, Medical device, Vaccine, Pharmaceutical industry, Rare-earth element, Audit, Euro, Affimer

MANNHEIM, Germany, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the third quarter of 2023.

Key Points: 
  • MANNHEIM, Germany, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the third quarter of 2023.
  • Total revenue for the quarter ended September 30, 2023, was €2.0 million compared with €14.9 million for the quarter ended September 30, 2022.
  • Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the IASB.
  • Affimed will host a conference call and webcast on November 14, 2023, at 8:30 a.m. EST / 14:30 CET to discuss third quarter 2023 financial results and corporate developments.

Affimed Announces Acimtamig as International Nonproprietary Name for AFM13

Retrieved on: 
목요일, 11월 9, 2023
WHO, FDA, International, PTCL, INN, Affimer, Cell, Neoplasm, World Health Organization, Cancer, Patient, Pharmaceutical industry

MANNHEIM, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) has selected "acimtamig" for the nonproprietary name of the Company’s investigational drug for CD30-positive Lymphomas, previously known as AFM13.

Key Points: 
  • MANNHEIM, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) has selected "acimtamig" for the nonproprietary name of the Company’s investigational drug for CD30-positive Lymphomas, previously known as AFM13.
  • Following the WHO nomenclature scheme, the name recognizes the drug as a tumor targeting bispecific antibody.
  • “Selection of the INN acimtamig by the WHO is an important milestone in the clinical development of AFM13 with initiation of the LuminICE-203 study underway,” said Dr. Adi Hoess, Chief Executive Officer at Affimed.
  • “It adds to the momentum of the fast track designation awarded by the FDA earlier this year to the acimtamig and AlloNK® combination.

Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023

Retrieved on: 
화요일, 11월 7, 2023
EST, Cancer, Patient, Webcast, Affimer, Pharmaceutical industry

MANNHEIM, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2023 results and corporate update on Tuesday, November 14, 2023.

Key Points: 
  • MANNHEIM, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2023 results and corporate update on Tuesday, November 14, 2023.
  • The Company will host a conference call at 8:30 a.m. EST / 14:30 CET.
  • The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/ .
  • Note: To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.

Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Retrieved on: 
금요일, 11월 3, 2023
IZI, Society for Immunotherapy of Cancer, Affimer, Engineering, Poster, SITC, Immunotherapy, ADCC, NK, Cell therapy, Society, Cancer, Patient, Fraunhofer Society, Fertilizer, Vaccine

“This is the first direct comparison of NK cells redirected by Affimed’s ICE® with CAR-NK cells,” said Dr. Arndt Schottelius, Chief Scientific Officer at Affimed.

Key Points: 
  • “This is the first direct comparison of NK cells redirected by Affimed’s ICE® with CAR-NK cells,” said Dr. Arndt Schottelius, Chief Scientific Officer at Affimed.
  • The combination of allogeneic NK cells with ICE® molecules represents the most straightforward way to generate potent and targeted NK cells.
  • The combination of the ICE® molecule with NK cells or CAR-NK cells enhanced antibody-dependent cellular cytotoxicity (ADCC) against tumor cells and mediated elevated levels of degranulation when compared to NK cells or CAR-NK cells alone.
  • In conclusion, the combination of NK cells with ICE® represents a straight-forward way to potently target and activate NK cells.

Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

Retrieved on: 
목요일, 11월 2, 2023
Cord blood, Patient, Lymphoma, HL, PTCL, EST, Cell, GVHD, Affimer, Society, ASH, CFGB-FM, PST, NK, Relapse, Cytokine release syndrome, Abstract, Annual general meeting, Natural killer T cell, ORR, EFS, Haematopoietic system, University, Exposition, Safety, CRS, Cancer, Peripheral T-cell lymphoma, MD Anderson Cancer Center, Investigational New Drug, Pharmaceutical industry, Vaccine, Leukemia

A total of 42 patients were enrolled in the study with 36 patients treated at the RP2D.

Key Points: 
  • A total of 42 patients were enrolled in the study with 36 patients treated at the RP2D.
  • All patients were heavily pretreated and refractory to their most recent line of therapy with active progressive disease at the time of enrollment.
  • A more in-depth analysis of the data and updated EFS/OS data using a later cut-off date will be presented during Dr. Nieto’s oral presentation.
  • The second presentation will be a poster featuring the design of Affimed’s phase 2 LuminICE-203 clinical trial investigating AFM13 in combination with Artiva’s AlloNK® (also known as AB-101), an allogeneic, non-genetically modified NK cell therapy candidate.

Mestag Therapeutics announces the appointment of expert advisors Dr. Cassandra Choe-Juliak, Dr. Greg Elson and Samantha Vieira MBA

Retrieved on: 
목요일, 10월 12, 2023
Bachelor of Science, Ipsen, Bispecific monoclonal antibody, Affimer, MBA, Receptor (biochemistry), Acquisition, Doctor of Philosophy, MS, Development, Henley Business School, Breast, PMP, Multiple myeloma, University, AMAL, VCU Medical Center, Boehringer, Glenmark Pharmaceuticals, Biosimilar, Therapy, Georgetown University, Medical college, Merck, University of the Witwatersrand, Nightstar, Publication, Biogen, Lung, Selinexor, EMBA, Boehringer Ingelheim, XPO, Patient, Pharmaceutical industry, Molecular Immunology, Physiology, MD

"Mestag is honored to appoint Dr. Choe-Juliak, Dr. Elson and Ms Vieira to our advisory team.

Key Points: 
  • "Mestag is honored to appoint Dr. Choe-Juliak, Dr. Elson and Ms Vieira to our advisory team.
  • Cassandra Choe-Juliak, MD, MS, has spent more than 17 years in oncology medical affairs and clinical drug development.
  • Greg Elson, PhD, is co-founder and managing partner at Prevail Biopharma Solutions, and Chief Technology Officer at Alentis Therapeutics.
  • Samantha holds an EMBA from Henley Business School and BSc (Honours) in Physiology from University of the Witwatersrand, South Africa.

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

Retrieved on: 
화요일, 9월 12, 2023
Hodgkin lymphoma, Affimer, Non-Hodgkin lymphoma, Cancer, Fast Track, NK, Patient, Collection, HL, CR, FDA, IND, ORR, Safety, Pharmaceutical industry

The combination treatment is entering Phase 2 development and will be investigated in Affimed’s LuminICE-203 study ( NCT05883449 ), which received IND-clearance earlier this year; the study also includes an exploratory cohort of CD30-positive peripheral T-cell lymphoma patients.

Key Points: 
  • The combination treatment is entering Phase 2 development and will be investigated in Affimed’s LuminICE-203 study ( NCT05883449 ), which received IND-clearance earlier this year; the study also includes an exploratory cohort of CD30-positive peripheral T-cell lymphoma patients.
  • “Our clinical data of AFM13 in combination with allogeneic NK cells has shown outstanding efficacy and a well-managed safety profile in late-stage, muti-refractory, patients with r/r Hodgkin and Non-Hodgkin lymphoma,” said Dr. Wolfgang Fischer, Chief Operating Officer at Affimed.
  • The FDA’s decision is based on available data showing the potential of the AFM13 and AlloNK® combination therapy to overcome current limitations in the treatment of r/r HL.
  • With the Fast Track Designation, the therapeutic development of the combination can benefit from more frequent engagement with the FDA, which will support the collection of appropriate data needed to accelerate its development.

Affimed to Present at the H.C. Wainwright Annual Global Investment Conference

Retrieved on: 
목요일, 9월 7, 2023
Cancer, Time in Europe, Patient, Conference, Affimer

HEIDELBERG, Germany, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 11:00 a.m. Eastern Daylight Time / 17:00 Central European Time.

Key Points: 
  • HEIDELBERG, Germany, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 11:00 a.m. Eastern Daylight Time / 17:00 Central European Time.
  • A live webcast of the presentation will be accessible on Affimed’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/ .
  • A replay of the call will be archived on Affimed’s website for 30 days after the call.
  • For more information on the conference or to schedule a one-on-one meeting with Affimed management, please contact your conference representative, or Alex Fudukidis via email at [email protected] or phone at +1 (917) 436-8102.

Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

Retrieved on: 
화요일, 8월 22, 2023
PK, Probability, Half-life, Serum, Affimer, Cancer, Orientation, Antibody, Patient, Manuscript, Neonatal Fc receptor, Pharmaceutical industry, Vaccine

“The earlier we know which antibody format has the highest probability to succeed in the clinic, the better,” states Dr. Arndt Schottelius, Chief Scientific Officer at Affimed.

Key Points: 
  • “The earlier we know which antibody format has the highest probability to succeed in the clinic, the better,” states Dr. Arndt Schottelius, Chief Scientific Officer at Affimed.
  • Identification of antibody candidates with optimal PK properties can therefore inform on the antibody with the best clinical developability.
  • The PK profiles of therapeutic antibodies in vivo are largely governed by their pH-dependent binding to the human neonatal Fc receptor, FcRn.
  • sequence of antigen-binding domains, as well as number, structure, and orientation of these domains significantly alters the FcRn dissociation pH.

Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress

Retrieved on: 
목요일, 8월 10, 2023
Insurance, ASH, Cholangiocarcinoma, American Society of Clinical Oncology, Patient, EGFR, International Financial Reporting Standards, IASB, Hematology, International Accounting Standards Board, NK, Genentech, Lung cancer, 2023 International Conference on Climate Resilient Pakistan, Cytokine release syndrome, FDA, IND, Conference, Book, Safety, Hodgkin lymphoma, Interim, International, MSS, Non-Hodgkin lymphoma, Cancer, Record, NSCLC, Cell, Acute myeloid leukemia, Colorectal cancer, Roivant Sciences, HL, CR, Webcast, Research, ORR, PTCL, PK, CRC, Bank statement, Lymphoma, Clinical trial, NHL, EDT, CFGB-FM, Trial of the century, AML, Financial toxicity, Society, Pharmaceutical industry, Audit, Cryptocurrency, Euro, Affimer

AFM24 combinations: Affimed plans to report data from the combination with atezolizumab in the fourth quarter 2023; data from combination study with SNK01 were presented at ASCO Breakthrough.

Key Points: 
  • AFM24 combinations: Affimed plans to report data from the combination with atezolizumab in the fourth quarter 2023; data from combination study with SNK01 were presented at ASCO Breakthrough.
  • HEIDELBERG, Germany, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the second quarter of 2023.
  • Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the IASB.
  • Affimed will host a conference call and webcast on August 10, 2023, at 8:30 a.m. EDT / 14:30 CET to discuss second quarter 2023 financial results and corporate developments.